Biologics and Biomanufacturing: development of support technology


Funding period: 2014-2019
Lead: Bernard Massie
Total GRDI funding: $4,440,000

The GRDI supports the Biologics and Biomanufacturing program, which covers all aspects of development from discovery up to pre-clinical testing in collaboration with industrial partners. Using genomic, proteomic and bioinformatic approaches, promising targets are identified based on their cancer-associated profiles. Hundreds of antibodies are then made against these targets and screened for specificity and function. NRC scientists are adapting this pipeline to immunotherapy using antibody-drug conjugates. These are revolutionizing the field of cancer chemotherapy by combining the targeting specificity of antibodies with the killing potential of cellular toxins for high efficacy and low toxicity.

Contact us

For additional information, please contact:
Genomics R&D Initiative